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characterization of the MMP enzyme family and report on 
the latest findings on issues arising from experimental stud-
ies.  Methods: A Medline search using the following key 
words was performed: matrix metalloproteinases + sponta-
neous intracerebral hemorrhage/intracranial hemorrhage/
bleeding/hemorrhagic stroke. We accepted studies report-
ing on MMP expression in adult patients with spontaneous 
ICH, as well as its relation to radiological and clinical features 
and patients’ outcome. For the final review, 18 clinical stud-
ies were considered. MMP inhibition was reviewed on the 
basis of 11 relevant experimental studies. Also, some rele-
vant reports on the biology of MMPs and their pathophysiol-
ogy in ICH were reviewed.  Results and Conclusions: Many 
studies provide convincing evidence of a detrimental role of 
MMPs in ICH, stressing their association with neuroinflam-
mation. The role of MMPs in hemorrhagic stroke appears 
critical for hematoma and brain edema growth as well as for 
neuronal death, which are understood as secondary brain 
injury and may have a considerable clinical impact. Although 
data on human spontaneous ICH are scarce and mostly 
based on small populations, they reveal the apparent corre-
lation between MMPs and clinical and radiological ICH fea-
tures as well as the functional outcome, which might ratio-
nalize future therapeutic strategies. However, attempts at 
MMP inhibition in spontaneous ICH have solely been made 
under experimental conditions and were associated with a 
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 Abstract 
 Background: In default of a plausible and satisfactory caus-
al treatment for hemorrhagic stroke, a role of matrix metal-
loproteinases (MMPs) in the pathogenesis of cerebrovascu-
lar diseases has recently been widely discussed. The well-
known impact of MMPs on extracellular matrix destruction 
triggered by inflammation as a foundation for several dis-
eases, including stroke, is very much in evidence. Newly, 
some additional aspects of MMP function considering their 
intracellular activity crucial for neuronal death following 
ischemic brain damage have emerged. The effect of blood-
brain barrier disruption caused by MMPs on the prognosis in 
patients suffering from spontaneous intracerebral hemor-
rhage (ICH) has been of interest since it throws a new light 
upon the pathogenesis, course and possible therapeutic ap-
proaches for this least treatable and at the same time most 
life-threatening form of stroke. Hence, we primarily aimed to 
review the current clinical knowledge on the significance of 
metalloproteinase activation in the course of spontaneous 
intracranial hemorrhage in humans. We also provide a brief 
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wide range of possible side effects. Therefore, further com-
prehensive, elucidating investigations in this field are vital 
before any conclusions could be translated to humans. 
 Copyright © 2012 S. Karger AG, Basel 
 Introduction: New Challenges in the Pathogenesis 
of Spontaneous Intracerebral Hemorrhage 
 Cerebrovascular research, as yet sparingly focused on 
hemorrhagic stroke, unlike the case of ischemic insults, 
has not established any milestones in the therapy of this 
severe condition. Furthermore, it seems to prove the 
unique and very complex nature of this type of stroke. 
This section is intended to provide a brief summary re-
garding recent interest in the course of spontaneous in-
tracerebral hemorrhage (ICH).
 Spontaneous ICH accounts for about 15% of all stroke 
cases, and up to 50% of patients with this condition die 
within 1 month after onset  [1] . Age, intraventricular 
bleeding extension, baseline hematoma size and Glasgow 
Coma Scale score but first and foremost hematoma 
growth within the first 24 h as crucial for the prognosis 
in spontaneous ICH patients were recently intensively 
studied with the hope of achieving a better understand-
ing of the pathogenesis of spontaneous ICH  [2, 3] . The 
Factor Seven for Acute Hemorrhagic Stroke Trial failed 
to confirm clinical benefit of applying recombinant fac-
tor VIIa as early treatment of spontaneous ICH  [4] . Al-
though significant hematoma growth reduction was 
shown after recombinant factor VIIa administration, it 
has been pointed out that inadequate patient selection 
could have counterbalanced the primarily promising ef-
fects  [5, 6] .
 Nevertheless, bleeding growth remains an important 
target when considering new therapeutic approaches.
 When discussing the phenomenon of bleeding forma-
tion and enlargement after ICH, the significance of peri-
hematomal edema (PHE) needs to be raised. Xi et al.  [7] 
hypothesized edema formation to be vital in secondary 
brain injury after spontaneous ICH onset, contributing 
to blood-brain barrier (BBB) damage and hematoma en-
largement. PHE formation was shown to start as soon as 
3 h after spontaneous ICH onset and to increase even up 
to 14 days  [8, 9] . Gebel et al.  [10] proved relative PHE 
(PHE volume divided by hematoma volume measured on 
baseline brain CT scans) to be an independent predictor 
of poor neurological outcome but not mortality 3 months 
after spontaneous ICH onset. However, the pivotal role in 
edema formation has been assigned to the thrombolytic 
cascade and production of thrombin within 24 h. It is 
worth noting that expression of prothrombin mRNA ad-
ditionally by neurons, without opening of the BBB, can 
amplify that effect by directly promoting the develop-
ment of edema and enhancing inflammation  [11] . Throm-
bin may also induce brain edema development by influ-
encing the c-Jun N-terminal kinase pathway. Michel-Mo-
nigadon et al.  [11] showed that c-Jun N-terminal kinase 
inhibition reduced brain edema after experimental brain 
hemorrhage.
 Thus, the origin of primary PHE after spontaneous 
ICH is vasogenic and not cytotoxic, as it develops due to 
an increase in the permeability of the BBB after the onset 
of ICH and is triggered by proinflammatory agents  [7] .
 Matrix Metalloproteinases: Profile and Properties 
 Matrix metalloproteinases (MMPs) together with oth-
er proteases such as serine or cysteine proteases belong to 
the group of endopeptidases. They play a unique role in 
remodeling of extracellular matrix (ECM) due to their 
ability to splinter its integrity. This makes them important 
contributors in many physiological processes including 
blastocyst implantation, embryonic development, nerve 
growth, endometrial cycling, mammary gland morpho-
genesis, bone remodeling, wound healing, angiogenesis 
and apoptosis. Also of the utmost importance is their par-
ticipation in a number of pathologic processes; MMPs are 
ubiquitously employed, for example, in cancer invasion 
and metastasis. Moreover, they are assumed to induce tis-
sue destruction in, for example, aortic aneurysm, rheu-
matoid arthritis, gastric ulcer, dilated cardiomyopathy 
and fibrotic lung disease as well as in many diseases of the 
central nervous system  [12–14] . They also promote anoi-
kis – cell death due to homelessness – as a result of matrix 
disintegration  [14] . Intracellular MMP function has been 
widely studied, providing new insight into the role of this 
enzyme family. MMPs have been shown to invade cells in 
the process of endocytosis and to take part in protein 
cleavage in the cytosol and in some of the organelles  [15] . 
More importantly, as reviewed by Mannello and Medda 
 [16] , some MMPs can enter the cellular nucleus and influ-
ence gene transcription and DNA repair, leading to de-
creased function of poly-ADP-ribose polymerase-1 
(PARP-1) and X-ray repair cross-complementing pro-
tein-1, which are responsible for the process of DNA repa-
ration. This in turn results in apoptosis.
 MMPs along with seralysins, astacins and adamaly-
sins or a disintegrin and metalloproteinase (ADAMs)/
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ADAMs with thrombospondin motifs are also known as 
metizins because of the specific structure of their cata-
lytic domain containing a zinc atom  [13] .
 In fact, there are three functional domains that form 
the MMPs structure and which determine the idiosyn-
crasy of the MMPs, merging these 24 enzymes into one 
superfamily of zinc peptidases. The basic constellation 
comprising a signaling peptide (predomain), propeptide 
(prodomain) and catalytic domain is identical to the 
smallest MMP, called matrilysin (MMP-1). With the 
broadening of knowledge regarding MMPs, the termi-
nology used to name these enzymes has been changing. 
Nevertheless, the system based on substrate specificity is 
still widely used. It comprises 8 subgroups named after 
their substrates: matrilysins, collagenases, stromelysins, 
gelatinases, convertase-activatable MMPs, membrane-
associated MMPs, MMP-23A and MMP-23B ( fig. 1 ). Al-
together, MMPs are responsible for entire ECM remodel-
ing  [13] .
 Under normal quiescent conditions, MMPs expres-
sion is very limited and MMPs are detected either in 
small amounts or not at all in tissues or in the circulation.
 Usually MMPs are synthetized as nonactive, latent 
forms called zymogens. Their latency is maintained by 
preserving the pre-/prodomain structure. This is achieved 
by coordination between the Zn 2+ ion in the catalytic do-
 Fig. 1. Structural division of MMPs based on Overall and López-Otín [13]. The diagram represents 8 indepen-
dent subgroups of MMPs, which are all based on the minimal domain set. The hemopexin domain differs 
slightly among the subgroups, thus determining the substrate specificity. Additional inserts and domains pro-
vide further specificity differentiations between the subgroups (graphic by M. Florczak-Rzepka and A. 
Sułkowska). 
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main and the SH group of unpaired cysteine in the high-
ly conserved sequence in the prodomain ( fig. 2 )  [17] .
 Importantly, the activation of MMPs is regulated on 3 
main levels, starting with transcription, through acti-
vation of latent forms and ending up at the inhibition lev-
el  [14] . The next three sections are devoted to these pro-
cesses.
 MMP Activation 
 Following signal peptide removal in the process of 
translation, usually inactive MMPs are secreted into the 
extracellular space to be activated there ( fig. 3 ). However, 
recent studies on intracellular MMP activity provide ev-
idence that the MMP activatory process may also take 
place inside the cell  [15, 16] .
 Crucial for enzymatic activation of MMPs is cleavage 
of the cysteine-zinc bridge (6- to 10-kDa N-terminal pro-
peptide cleavage) in the process called ‘cysteine switch’. 
This leads to exposure of the zinc atom to water mole-
cules and the thiol group to a substrate  [17] . Afterwards, 
the prodomain is cleaved in a process called autocatalysis. 
Thus, the latent MMP form – proform or zymogen – be-
comes an active, lower-molecular weight MMP. There are 
at least 3 mechanisms by which the Cys-Zn coordination 
is broken, as reviewed by Cauwe and Opde nakker  [15] . 
The main MMP activatory pathways are schematically 
depicted in  figures 2 and  3 and described below:
 (1) The first of these is proteolytic cleavage, which 
depends on catalytic site opening by proteases. The spe-
cial role of serine proteases in this process may be ex-
plained by their involvement in many intra- and extra-
cellular processes, such as the coagulation cascade. Plas-
min, which belongs to the serine protease family, 
localizes in the vicinity of fibrin deposition or on mobi-
lized cells, which allows it to take part in diverse pro-
cesses such as fibrinolysis and ECM decomposition dur-
ing cell migration. This specific localization is guaran-
teed by the proenzyme form, plasminogen, but firstly by 
the close proximity to plasminogen activator, which in 
turn depends on the type of plasminogen activator; tis-
sue plasminogen activator anchors fibrin, whereas uro-
kinase plasminogen activator sticks to membrane re-
ceptors  [18] .
 Fig. 2. Autocatalysis in the process of 
MMPs activation. Prodomain cleavage 
may occur either extracellularly or inside 
cells as a result of several processes. The 
best known is direct proteolysis mediated 
by serine proteases or other active MMPs. 
Free oxygen or nitrogen radicals (reactive 
oxygen species/reactive nitrogen species) 
may cause disruption of the Cys-Zn inter-
action. Allosteric activation causes distor-
tion of the catalytic site in MMPs. All reac-
tions are followed by prodomain cleavage, 
which definitely leads to MMP activation. 
All depicted pathways occur extracellular-
ly. Proteolysis and activation by reactive 
oxygen species/reactive nitrogen species 
can also occur inside cells. More details on 
MMP activation are to be found in the text 
(graphic by M. Florczak-Rzepka and A. 
Sułkowska). 
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 Intracellular proteolytic activation depends on furin, 
one of the serine peptidases that was found to cleave some 
MMPs, like MMP-11 and membrane-type 1 (MT1)-MMP 
in the trans-Golgi apparatus network  [19, 20] .
 The link between serine proteinases and MMP activa-
tion builds up a complicated system of interactions and 
was therefore named the ‘protease web’ or ‘internet’, 
whereby active MMPs activate other MMPs  [21] .
 An example of such a relationship is the MMP-2 acti-
vatory pathway, which is promoted by active MT1-MMP. 
This also applies to gelatinase B (MMP-9) and MMP-13. 
Interestingly, in the process of MMP-2 liberation, bind-
ing to tissue inhibitor of MMP (TIMP)-2 is required  [12, 
14, 22]  ( fig. 3 ).
 (2) Any cell injury may lead to an imbalance between 
the production and disposal of reactive oxygen species or 
reactive nitrogen species, causing oxidative or nitrosa-
tive stress, respectively. Oxygen or nitrogen free radicals 
may interact with the thiol group in the prodomain and 
expose catalytic zinc to bind with water molecules and 
so activate the MMP. An interesting fact is that a low 
concentration of some free radicals may activate some 
zymogens, such as pro-MMP-7  [23] , but at the same 
time, prolonged exposure to free radicals and their per-
sistent high concentration may, in contrast, inactivate 
some MMPs. Eventually, it was shown that in some cas-
es there is no ultimate need for prodomain cleavage to 
achieve an active state of MMPs in the presence of free 
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radicals. Therefore, the MMP proform is no more equiv-
alent to the latent form or zymogen. Similar modifica-
tion of the thiol group may also occur in the presence of 
nonphysiological agents, like heavy metal ions or alkyl-
ating reagents  [15] .
 (3) Allosteric activation of MMPs consists of shape 
modification of the catalytic site in the MMP molecule. 
The same effect may be achieved by attaching a substrate, 
mainly nonphysiological agents, to the thiol group and 
disruption of the Cys-Zn coordination.
 All the activatory pathways take place in the extracel-
lular space  [15] .
 The intracellular MMP activation process, as reviewed 
by Cauwe and Opdenakker  [15] , includes proteolysis and 
oxidative/nitrosative stress but also phosphorylation me-
diated by alkaline phosphatase, which was shown in the 
case of MMP-2 activation. Most frequently this process 
occurs in MMPs containing a fibronectin-like domain, 
but it has also been shown in the case of MT1-MMP in its 
cytoplasmatic domain.
 Alternatively to prodomain cleavage, it was found that 
low-molecular weight MMPs lacking signal peptide and 
propeptide may be expressed in a process called alterna-
tive splicing, as in the case of MMP-11  [15] .
 Gene Expression 
 A wide range of factors can induce MMPs transcrip-
tion. Some data based on cancer research indicate the role 
of growth factors, cytokines and oncogene products. Typ-
ically they are released by the matrix or infiltrating host 
defense cells but also by tumor cells themselves. Addition-
ally, every change in the cell vicinity such as form altera-
tions of the cell or mechanical stress can also trigger 
MMPs transcription. As yet, there is no single agent that 
has been found to be exclusively responsible for activating 
MMPs gene expression  [13] . Nuclear factor (NF)-  B and 
other nuclear factors, as well as tumor necrosis factor-  
(TNF-  ), interleukin (IL)-1  and IL-6, are also constant-
ly involved in the MMPs expression process  [13, 24] ( fig. 4 ). 
Synthesis Activity spectrum
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 Fig. 4. MMP regulation pathway. Selection of the most frequently involved factors and the scope of MMPs.
uPA = Urokinase plasminogen activator; ROS = reactive oxygen species; SNP = single-nucleotide polymor-
phism; TGF-  = transforming growth factor   . 
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By virtue of the variability in the promoter of MMP genes, 
another level of MMP diversity opens. Single-nucleotide 
polymorphisms may modify the processing of mRNA and 
consequently the activity of expressed proteases. It has 
been reported that a 736-base pair region in the promoter 
sequence of the gene encoding MMP-9 containing a cyto-
sine-adenosine repeat may vary in length from 13 to up to 
23 repeats in the human population and is associated with 
susceptibility to intracranial aneurysms  [25] . In fact, one 
should consider that a polymorphism is merely a variation 
of the normal sequence, and hence, small-sample studies 
may not have enough power to demonstrate any pheno-
typic effect of such a genetic variant.
 MMP Inhibition 
 Attenuation of MMPs activity is crucial to counterbal-
ance their proteolytic extra- and intracellular activity 
 [17] . There are several ways to inhibit MMPs, firstly by 
targeting factors that may possibly induce MMPs gene 
expression and secondly by influencing MMPs activity.
In fact, there are two physiological MMP inhibitors
(MMPIs). Outside tissues, in the plasma,   2-macroglob-
ulin binds to MMPs, creating an irreversible complex. In-
side tissues, specific TIMPs were found to be mainly re-
sponsible for regulation of MMPs activity  [16] .
 Inhibition is achieved through formation of tight 1: 1 
noncovalent complexes with TIMPs. Four types of these 
natural inhibitors have been described so far, and each 
one is able to interact with any of the MMPs. However, 
there is a clear proclivity towards some combinations be-
tween MMPs and their inhibitors, such as TIMP-1-
MMP-2 and TIMP-2-MMP-9  [17] . It is also worth notic-
ing at this point that in the case of TIMP-2 and -3, lower 
concentrations can enhance rather than inhibit MMP-2. 
Inversely, at higher concentrations, MT1-MMP is entire-
ly blocked, which results in a purely inhibitory effect on 
MMP-2  [18, 26] ( fig. 3 ).
 However, the role of TIMPs is complex and extends 
beyond a strictly inhibitory effect on MMPs, at least in 
the case of cerebral ischemia  [27, 28] .
 What Is the Link between the Function of MMPs and 
the Pathogenesis of ICH? 
 ICH is a massive event, destroying brain tissues by in-
duction of several mechanisms. Primary brain injury oc-
curs within minutes after ICH onset and is related to the 
extravasated blood mass itself but also to the cell debris 
and plasma proteins. As described by Aronowski and 
Zhao  [29] , erythrocytes are lysed within 24 h, releasing 
hemoglobin along with its derivatives, including heme 
and iron, which are both capable of evoking oxidative cell 
damage by generating free radicals. It seems that the pro-
tective role of haptoglobin in building complexes with 
free hemoglobin, thus preventing its toxicity, is insuffi-
cient, as its recovery process, mostly by the liver, lasts 5–7 
days. However, there is some evidence that haptoglobin 
may be produced at the site of bleeding. Nevertheless, it 
was also reported by the same group that in the course of 
ICH, endogenous antioxidative mechanisms may be de-
pressed, such as that mediated by Nrf2. This was con-
firmed using Nrf2-knockout mice, which had much more 
extensive brain tissue injury than wild types after in-
duced ICH  [30] . Fortunately, peroxisome proliferator-ac-
tivated receptor-  -induced antioxidative enzyme (cata-
lase) production was shown to be upregulated in experi-
mental ICH  [31, 32] .
 The second part of the posthemorrhagic brain injury 
occurs in parallel and starts within hours from the ictus. 
Mediated by adhesion molecules, leukocyte infiltration 
as well as activation of other immune cells (macrophages, 
microglia, astroglia) results in cytokines (e.g. IL-1  , 
TNF-  ) and chemokines overexpression. The main in-
flammatory pathway signaling molecule is thought to be 
NF-  B, which affects gene transcription of the above-
mentioned key adhesion molecules, cytokines and che-
mokines as well as MMPs ( fig.  4 )  [33–36] . Secondary 
brain injury results in disruption of the BBB, brain edema 
and massive neuronal death. The role of MMPs in both 
processes seems to be fundamental.
 In the central nervous system, the basement mem-
brane (BM) has a pivotal role for preserving the function 
of the BBB, which is made up of the following types of 
cells: perivascular endfeet of astrocytes, glia (microglia), 
pericytes, neuronal processes and the basal lamina (BM). 
The latter consists mainly of type IV collagen, laminin, 
fibronectin and elastin ( fig. 5 )  [14, 18, 37] .
 For a better understanding of the association between 
some MMPs and BBB breakdown, some facts need to be 
recalled. The remodeling of ECM in the whole organism 
by MMPs is guaranteed by the affinity of each group of 
MMPs to particular substrates. Interestingly, the ability 
to digest type IV collagen makes gelatinases A and B 
(MMP-2 and MMP-9, respectively) unique among other 
proteases and determines their role in BBB damage. In 
this case, binding to the BM is possible due to a fibronec-
tin-binding region, a unique additional domain in the 
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structure of this specific group of MMPs ( fig.  1 )  [37] . 
Apart from this extracellular MMP function, there is also 
another, intracellular part.
 Preservation of BBB function is guaranteed by tight 
junction (TJ) protein complexes within the endothelium 
( fig. 5 ). A TJ is a type of connection between two endo-
thelial cells which limits transfer of substances and water 
through the BBB. The intercellular part of the TJ consists 
of claudins and occludins, which are attached to the in-
tracellular scaffold made up of zona occludens proteins 
(1, 2, 3) and cingulin anchored in the cytoskeleton. As 
described by Cauwe and Opdenakker  [15] , MMPs were 
shown to attack zona occludens-1, causing its cleavage 
and TJ disruption.
 Moreover, as already mentioned, MMPs may directly 
contribute to cellular death either by anoikis or by their 
intranuclear function. It was found that furin may acti-
vate MMPs inside cell nuclei and active enzymes are able 
to cleave PARP and PARP-activated X-ray repair cross-
complementing protein-1 – both molecules take part in 
the DNA reparation process following oxidative stress 
damage  [15] .
 Macrophage metalloelastase (MMP-12) has been found 
to be highly overexpressed in the area around hematoma. 
It was also demonstrated to be a key molecule that corre-
lates with outcome in experimental ICH. Nevertheless, 
MMP-12 has been widely neglected in recent inquires and 
not yet considered in clinical investigations  [38] .
 Interestingly, Mun-Bryce et al.  [39] used somatic 
evoked potentials in hemorrhagic stroke to show the de-
pressed cortical response, also contralateral to the hema-
toma site, which was followed by overexpression of MMP-
9 and MMP-2 (gelatinases), implying that neuroinflam-
mation triggered by blood extravasation in the course of 
ICH is not limited to the directly damaged brain tissue. 
This may suggest that the inflammation in the course of 
ICH is not only localized to the lesion but also involves 
distant areas.

 Fig. 5. BBB destruction by MMPs during 
the inflammatory process based on Ab-
bott et al. [37]. The process includes fibri-
nolytic cascade, oxidative stress, neutro-
phil infiltration and activation of immune 
cells, e.g. microglia. All involved cells 
along with stimulated endothelium release 
cytokines and chemokines as well as 
MMPs. Invasion into the brain is followed 
by destruction of TJ proteins and BM de-
composition caused by activated MMPs. 
t-PA = Tissue plasminogen activator. Fur-
ther information is provided in the text 
(graphic by M. Florczak-Rzepka and A. 
Sułkowska). 
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 Moreover, it has been postulated that the inflamma-
tory cascade in hemorrhagic brain extends beyond it 
and is reflected in increased concentrations of inflam-
matory biomarkers in the peripheral blood. This is 
probably due to increased expression of cytokines such 
as TNF-  , IL-1  and specifically IL-6, which triggers 
production of acute-phase proteins in the liver such as 
C-reactive protein (CRP) and fibrinogen, thus amplify-
ing inflammation ( fig. 3 )  [40] .
 Summing up, MMPs play a crucial role in secondary 
brain injury following neuroinflammation, leading to 
opening of the BBB, apoptosis and both vasogenic and 
cytotoxic brain edema following ICH.
 MMPs and Human Spontaneous ICH 
 Rosenberg  [41] was one of the first to describe the 
causative connection between MMPs and stroke in ro-
dents. Power et al.  [38] described the activation profile 
and pathogenic aspects of MMP-2, -3, -7, -9 and -12 in the 
course of experimental ICH ( table 1 ).
 Clinically, MMPs have been associated with ischemic 
and hemorrhagic stroke. The MMP-9 concentration was 
found to predict hemorrhagic transformation after cere-
bral ischemia. The ability of MMP-9 to cleave the compo-
nents of the BBB was proposed as a possible explanation 
for this correlation  [42] .
 To the best of our knowledge, Abilleira et al.  [43] were 
the first to describe overexpression of MMP-9 in human 
spontaneous ICH. They established the standard values 
for the plasma concentration of MMP-9 and other related 
biomarkers in healthy controls. Subsequently, they 
showed a direct correlation between MMP-9 plasma lev-
el, neutrophil count and relative perifocal edema (relative 
PHE = PHE/baseline spontaneous ICH) in deep hemato-
mas, as well as neurological worsening measured by 
means of the Canadian Stroke Scale, all measured within 
24 h after spontaneous ICH onset. This provides an im-
portant indication as to the significance of the BBB dis-
ruption of inflammatory origin in the course of sponta-
neous ICH. However, unlike in the case of deep hemor-
rhage, no significant relationship between the MMP-9 
concentration and the course of lobar bleeding was found, 
probably due to the small sample size.
 Early growth of the intracerebral bleeding in sponta-
neous ICH patients 48 h after onset was also proved to be 
associated with higher levels of MMP-9 and such molec-
ular factors as TNF-  , IL-6 and fibronectin, as well as
the common inflammatory markers leukocytes, platelets 
and fibrinogen  [44] .
 Importantly, MMP-9 and MMP-2 were also detected 
in the perihematomal area in humans within 6 h after 
death, and their concentration was higher in the affected 
than in the contralateral hemisphere  [36, 45] . Wu et al. 
 [46] confirmed the upregulation of MMP-9 in spontane-
ous ICH up to 5 days after hemorrhage onset. Addition-
ally, NF-  B, p65 and macrophage inflammatory pro-
tein-2 were overexpressed, showing predominance at the 
hematoma site.
 Another group carried out a prospective controlled 
study in 60 patients with spontaneous ICH who under-
went hematoma evacuation  [47] . The MMP-9 level was 
determined on days 1, 4 and 7 after neurosurgery in blood 
and cerebrospinal fluid (CSF). The MMP-9 level was 
higher in patients when compared with healthy controls 
Table 1.  An overview of the function of MMPs derived from human spontaneous ICH studies and ICH experimental models
ICH features MMP-2 MMP-3 MMP-7 MMP-9 MMP-12
Human spontaneous ICH
MMP overexpression yes [48]
no, up to day 5 [45]
yes [48] – yes [36, 44–46, 48] –
Correlation with ICH growth no [48] no [48] – yes [44] –
Correlation with PHE growth no [48]; yes [49] no [48] – yes [36, 44–46, 48, 
49]
–
Correlation with neurological deterioration no [48] yes [48] – yes [46] –
Experimental ICH
MMP mRNA induction yes [38, 41, 60];
max at day 7 [38]
yes – within
24 h [38, 60]
yes – within
24 h [38]
yes – on days 1
and 7 [38, 41, 60]
yes – on day 7 
[38]
Correlation with ICH growth – – – yes [58] yes [38]
Correlation with PHE growth – – – yes [58] yes [38]
Correlation with neurological deterioration – – – yes [58] yes [38]
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in both blood and CSF. Interestingly, there was no MMP-
9 found in normal CSF. Subsequently, these findings cor-
related positively with ICH and PHE volume as well as 
with the National Institutes of Health Stroke Scale score 
in the studied group of patients.
 Moreover, there is a certain pattern of release of MMP-
2, -3 and -9 after spontaneous ICH and thus also their 
inhibitors TIMP-1 and -2. The blood concentration of 
some of these molecules measured at different time points 
correlated with PHE volume and mortality within 3 
months after spontaneous ICH onset  [48] . Castellazzi et 
al.  [49] found increasing MMP-9 serum levels in sponta-
neous ICH patients within a week from admission. At the 
same time, MMP-2 decreased continuously. Neverthe-
less, MMP levels correlated with PHE volume, which in 
turn increased during the observational period  [9] . 
Hence, MMPs are likely to be involved in PHE formation 
and may have an impact on patients’ outcome. Thus, the 
time profile of MMP expression may be pivotal when 
thinking about future therapeutic aspects.
 Yamani et al.  [50] showed a relation between spontane-
ous ICH, enhanced MMP expression and subsequent de-
velopment of coronary vasculopathy in patients who un-
derwent heart transplant from spontaneous ICH donors. 
Increased MMP-2 and MMP-9 mRNA expression was 
found in the donors’ leukocytes and then in heart biopsies 
of the recipients 1 week after the surgical procedure. The 
MMP levels as well as the occurrence of coronary vascu-
lopathy and myocardial fibrosis were significantly higher 
in patients whose donors died of ICH than in patients 
whose donors died due to trauma. These results provide 
further evidence supporting the important role of neuro-
inflammation after spontaneous ICH as a generalized 
process which may influence the outcome after ICH not 
only resulting from the secondary brain injury.
 Wu et al.  [46] investigated the timing of secondary 
brain damage in patients with spontaneous ICH who un-
derwent hematoma evacuation. Apart from increased 
levels of MMP-9, they observed overexpression of cas-
pase-3 and proliferation of terminal uridine nick-end la-
beling-positive cells as early as 6 h after spontaneous ICH 
onset with the tendency to progression up to 24 h, limited 
by the duration of the observation. This was accompa-
nied by aggravated cell death and PHE, suggesting that 
secondary brain tissues damage occurs in the first few 
hours, at least up to 24 h after intracerebral bleeding on-
set and is primarily enhanced by apoptosis. Thus, the au-
thors raised again the controversial problem of the rele-
vance of early hematoma evacuation to improve patient 
outcome.
 Spontaneous ICH is mainly associated with arterial 
hypertension. In a recent population study, arterial hy-
pertension was found in 72.9% of patients with lobar ICH 
compared with 83.3% of cases presenting deep hemor-
rhages  [1] . However, often in elderly spontaneous ICH pa-
tients with no history of arterial hypertension, cerebral 
amyloid angiopathy (CAA) is the most likely cause of the 
bleeding. Interestingly, it was found that amyloid, which 
leads to cerebral vessel pathology in CAA, is mainly com-
posed of   -amyloid (the same as in Alzheimer’s disease) 
and can independently induce MMP-9, thus increasing 
the risk of spontaneous ICH in the elderly  [51] . Hernan-
dez-Guillamon et al.  [52] studied MMP-2 and MMP-9 ex-
pression in patients with CAA-related hemorrhagic stroke 
and in healthy controls. Although there was no difference 
in MMP plasma levels between ICH patients and controls, 
MMPs were upregulated in the perihe matomal area of 
brains in hemorrhagic patients when compared to the 
contralateral site of these brains and nonhemorrhagic 
brains. The authors also showed increased MMP-2 ex-
pression in   -amyloid-damaged vessels, whereas MMP-9 
was found in inflammatory cells.
 An important role of MMPs was also shown in the case 
of moyamoya disease. Fujimura et al.  [53] found increased 
MMP-9 serum levels in patients diagnosed with this con-
dition compared to normal MMP-9 levels found in healthy 
controls. This finding was not true for MMP-2, which re-
mained at the same level in both groups. The authors con-
cluded that this may facilitate pathological vascular pro-
cesses and thus cause brain hemorrhages.
 Finally, a deleterious role of MMPs was described
by many authors in the case of subarachnoid bleeding 
(subarachnoid hemorrhage, SAH). Since SAH is mainly 
caused by aneurysm rupture, it is not considered spon-
taneous ICH and thus formally exceeds the scope of this 
review. Nevertheless, some most recent facts regarding 
the involvement of MMPs seem worth remarking upon. 
Frösen et al.  [54] pointed out the role of inflammation 
and oxidative stress in the pathogenesis of intracranial 
aneurysm formation as the main cause of mural cell de-
generation and impairment of endothelial cell function. 
Interestingly, the International Study of Unruptured 
Aneurysms group recently published a report on a pos-
sible protective effect of aspirin in unruptured aneu-
rysms. In a group of 271 patients, they showed a trend 
toward a lower risk of hemorrhage due to aneurysm rup-
ture in patients under continuous aspirin therapy (3 
times weekly to daily)  [55] . This supports a role of in-
flammation in the pathogenesis of subarachnoid bleed-
ing. Chau et al.  [56] studied CSF and blood concentra-
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tions of MMP-9 and white blood cell (WBC) counts in 
35 SAH patients over 14 days. It was found that WBC 
and neutrophil count elevation over 2 weeks from SAH 
onset were independently associated with vasospasm. 
Also, WBC count and MMP-9 levels in the blood as well 
as CSF were related to poor clinical outcome (modified 
Rankin Scale score  1 2) within 3 months. They also 
found an association between WBC count and MMP-9 
levels in the blood as well as between blood and CSF 
MMP-9 concentrations. This in turn supports the role 
of leukocyte recruitment but also MMP-9 activation as 
crucial for the neuroinflammatory cascade. Another 
group found a significant relationship between SAH se-
verity as assessed by means of the World Federation of 
Neurosurgical Societies scale and pro-MMP-9 concen-
tration in CSF. Also, the MMP-9 preform was remark-
ably higher in patients who developed cerebral ischemia 
as a complication of SAH  [57] .
 Summing up, the role of MMPs in spontaneous ICH is 
evident. The early phase of the disease is characterized by 
a rapidly progressing inflammatory cascade, which leads 
to disruption of the BBB and spreads beyond the hemato-
ma. The enlargement of bleeding along with the formation 
of brain edema determines the extent of the secondary 
brain damage ( table 1 ). Moreover, it seems that the effect 
of the MMP-mediated response in the course of ICH may 
vary according to the MMP type. Prior studies imply that 
MMP-9 is involved in the acute phase, whereas MMP-2 
acts more in the chronic phase, which is compatible with 
results of basic science studies. Moreover, neuroinflamma-
tion and thus MMPs play an important role in the patho-
genesis of subarachnoid bleeding and its complications.
 These data are supported by findings derived from an-
imal models of spontaneous ICH highlighting the local 
origin of the inflammatory cascade, which disperses af-
terwards. In all experimental studies presented in  table 1 , 
either collagenase-induced ICH models or models with 
autologous blood injection into rodent brains were used.
 MMPs as Targets for Therapy 
 Given the unquestionable role of MMPs and foremost 
the gelatinases in the pathology of spontaneous ICH, 
their inhibition becomes an interesting issue regarding 
therapy of spontaneous ICH. So far, MMPs attenuation 
has been studied in a few experimental models of spon-
taneous ICH ( table 2 ). Interestingly, most of the inhibitors 
tested are derived from cancer research and were proved 
to act as possible antimetastatic agents. However, they are 
Table 2.  A selection of the possible means of inhibition of the MMPs tested so far using ICH models
Effect on 
experimental ICH
MMP inhibition MMP-9 knock-out
mice [36, 64]
b road-spectrum MMPIs
minocycline [38] BB-1101 [41] GM6001 [58] BB-94 [60]
Effect on MMPs decreased MMP-12,
no effect on MMP-2, 
-3, -7, -9
not assessed reduced MMP-9 activity not measured overexpression of 
MMP-2 and MMP-3, 
unchanged expression 
of MMP-7 [64]
Effect on
inflammation
and lesion size
decreased IL-1 
expression, reduced 
glial activation and 
cell death – effect 
seen on brain MRI
decreased sodium
and water content
reduced neutrophil 
infiltration, production of 
oxidative stress, brain 
edema and degeneration of 
neurons; decrease in injury 
volume within the first 3 
days after ICH
increased hemorrhage 
size and number of 
TUNEL-labeled cells, no 
reduction in brain water 
content, enhanced 
apoptosis
massive ICH, 
comparable BBB 
disruption, more 
pronounced 
microvessel bleeding 
and perifocal edema, 
reduced blood clotting 
time compared with 
wild-type mice [64]
smaller perifocal edema 
[36]
Effect on 
neurobehavioral 
outcome
improved neuro-
behavioral outcome 
on day 7
not assessed functional improvement not assessed increased mortality and 
neurological deficit 
compared to wild-type 
mice [64]
TUN EL = Terminal uridine nick-end labeling.
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mostly unspecific, which may explain their broad spec-
trum of function including some inevitable side effects 
mainly related to long-term suppression of the essential 
physiologic processes mediated by MMPs but also to in-
hibition of ADAMs and ADAMs with thrombospondin 
motifs  [21] . The most important MMPIs along with their 
brief profile in relation to ICH are listed in  table 2 .
 Wang et al.  [58] tested GM6001, a broad-spectrum me-
talloproteinase inhibitor administered intraperitoneally 
(100 mg/kg) in mice every 24 h for 2 days starting
2 h after ICH induction. They managed to demonstrate a 
significant reduction of the secondary brain damage due 
to leukocyte infiltration, MMP-9 activity and oxygen-de-
rived free radicals (reactive oxygen species). As a result, 
brain edema, neuronal loss and neurological deficit di-
minished on day 3 after ICH onset and treatment applica-
tion, confirming the crucial role of MMP-9 in the pathol-
ogy of the early deterioration after ICH.
 Lee et al.  [59] showed a link between MMP-9 but not 
MMP-2 overexpression in mouse brain tissues and vas-
cular endothelial growth factor-induced brain hemor-
rhage. In this model imitating brain arteriovenous mal-
formation-derived hemorrhage, minocycline suppressed 
ICH evolution, including significant reduction of the 
bleeding. A slightly smaller effect on hematoma was ob-
served when using pyrrolidine dithiocarbamate, inhibi-
tor of NF-  B, an upstream regulator of MMPs. These 
findings confirm that MMP-9 expression due to ICH can 
be regulated through different pathways, which is even 
more challenging in terms of possible inhibitory therapy.
 Quite interesting findings derive from another exper-
imental study where the authors tested the following non-
specific and specific MMPIs: BB-1101, BB-94, BB-2983, 
IW499, tetracyclines, steroids and DMSO (a selective 
MMP-2 and MMP-9 inhibitor). A significant reduction 
in BBB permeability was achieved when using BB-1101, 
BB-94, minocycline and 10% DMSO. Other substances, 
including GM6001 and the sole MMP-2 inhibitor IW499, 
were ineffective and did not reduce the leakage through 
the BBB  [41] .
 On the other hand, Grossetete et al.  [60] showed BB-94 
to increase hematoma with no effect on PHE. More im-
portantly, it also enhanced cell death.
 Although so far not considered in the group of
MMPIs, there are some agents that may be worth noting, 
as described below.
 Memantine, an uncompetitive N-methyl- D -aspartate 
receptor antagonist, reduced neuroinflammation, in-
cluding MMP-9 levels, and caused hematoma reduction 
by 47%  [61] .
 Sinn et al.  [62] demonstrated valproic acid to enhance 
alleviation of the inflammatory cascade and significant-
ly reduce bleeding as well as attenuate cell death in the 
perihematomal area after ICH in rats. The rationale pro-
vided refers to the ability of valproic acid to regulate gene 
expression and thus the possible alteration of the cyto-
kine profile involved in the pathophysiology of ICH.
 Final Considerations and Conclusions 
 Many data indicate the deleterious role of MMPs in 
the secondary brain damage following spontaneous ICH. 
At present, available clinical studies are scarce, mostly 
based on small populations and thus deliver merely a lim-
ited insight into the topic. However, the important role of 
MMPs in human spontaneous ICH in regard to the clin-
ical and radiological course of the disease as well as its 
impact on functional outcome seems to be already estab-
lished. A great number of rodent ICH studies strengthen 
this thesis by delivering promising data on MMPIs and 
MMP-9 knockout mice  [45] . Still, there are some appar-
ently inconsistent results from other knockout experi-
ments suggesting that the total blockade of MMPs may 
not be unquestionably advantageous  [63, 64] . However, 
some of these data are based on different experimental 
models of ICH, and thus conclusions should be drawn 
very carefully. Another reason for contrary findings may 
be the above-mentioned low specificity of many drugs 
tested for MMP inhibition.
 It should not be forgotten that MMPs as natural mol-
ecules in the human body are involved in a number of 
processes, which comprise other vital functions apart 
from the inflammatory cascade  [14, 24, 27, 65] .
 Hence, when considering blocking MMPs for thera-
peutic purposes, one has to be aware of their ubiquitous 
role in the human body and weigh the pros and cons care-
fully. The activity of MMPs, though, as crucial for the 
recovery phase after ICH, cannot be irreversibly blocked 
but merely modulated. Therefore, more properly de-
signed experimental studies are needed to define the crit-
ical point of the MMP-activating cascade before any con-
clusions can be transferred to clinical trials.
 Acknowledgements
 We wish to express our special thanks to Agnieszka and Bar-
tosz Sułkowscy for their professional help in visualizing the heart 
of the matter.
 
 MMPs in Human Spontaneous ICH Cerebrovasc Dis 2012;34:249–262 261
 References 
 1 Sacco S, Marini C, Toni D, Olivieri L, Carolei 
A: Incidence and 10-year survival of intrace-
rebral hemorrhage in a population-based 
registry. Stroke 2009; 40: 394–399. 
 2 Morgenstern L, Hemphill J III, Anderson C, 
Becker K, Broderick JP, Connolly ES Jr, 
Greenberg SM, Huang JN, MacDonald RL, 
Messé SR, Mitchell PH, Selim M, Tamargo RJ; 
American Heart Association Stroke Council 
and Council on Cardiovascular Nursing: 
Guidelines for the management of spontane-
ous intracerebral hemorrhage: a guideline for 
healthcare professionals from the American 
Heart Association/American Stroke Associa-
tion. Stroke 2010; 41: 2108–2129. 
 3 Steiner T, Kaste M, Forsting M, Mendelow D, 
Kwiecinski H, Szikora I, Juvela S, Marchel A, 
Chapot R, Cognard C, Unterberg A, Hacke 
W: Recommendations for the management 
of intracranial haemorrhage. I. Spontaneous 
intracerebral haemorrhage. The European 
Stroke Initiative Writing Committee and the 
Writing Committee for the EUSI Executive 
Committee. Cerebrovasc Dis 2006; 22: 294–
316. 
 4 Mayer SA, Brun NC, Begtrup K, Broderick J, 
Davis S, Diringer MN, Skolnick BE, Steiner 
T; FAST Trial Investigators: Efficacy and 
safety of recombinant activated factor VII 
for acute intracerebral hemorrhage. N Engl J 
Med 2008; 358: 2127–2137. 
 5 Bogousslavsky J, Piechowski-Jozwiak B: Pro-
thrombotic recombinant activated factor 
VII in intracerebral haemorrhage: FAST but 
not focused? Lancet Neurol 2008; 7: 670–672. 
 6 Mayer SA, Davis SM, Skolnick BE, Brun NC, 
Begtrup K, Broderick JP, Diringer MN, 
Steiner T; FAST trial investigators: Can a 
subset of intracerebral hemorrhage patients 
benefit from hemostatic therapy with re-
combinant activated factor VII? Stroke 
2009;40:833–840. 
 7 Xi G, Keep RF, Hoff JT: Pathophysiology of 
brain edema formation. Neurosurg Clin N 
Am 2002; 13: 371–383. 
 8 Brott T, Broderick J, Kothari R, Barsan W, 
Tomsick T, Sauerbeck L, Spilker J, Duldner J, 
Khoury J: Early hemorrhage growth in pa-
tients with intracerebral hemorrhage. Stroke 
1997; 28: 1–5. 
 9 Inaji M, Tomita H, Tone O, Tamaki M, Su-
zuki R, Ohno K: Chronological changes of 
perihematomal edema of human intracere-
bral hematoma. Acta Neurochir Supplement 
2003; 86: 445–448. 
 10 Gebel J Jr, Jauch E, Brott T, Khoury J, Sauer-
beck L, Salisbury S, Spilker J, Tomsick TA, 
Duldner J, Broderick JP: Relative edema vol-
ume is a predictor of outcome in patients 
with hyperacute spontaneous intracerebral 
hemorrhage. Stroke 2002; 33: 2636. 
 11 Michel-Monigadon D, Bonny C, Hirt L: c-
Jun N-terminal kinase pathway inhibition in 
intracerebral hemorrhage. Cerebrovasc Dis 
2010; 29: 564–570. 
 12 Kuittinen O: Matrix metalloproteinase-2 
(MMP-2) and -9 (MMP-9) in hematological 
malignancies. Acta Univ Oul D 712, 2003, pp 
1–82. 
 13 Overall CM, López-Otín C: Strategies for 
MMP inhibition in cancer: innovations for 
the post-trial era. Nat Rev Cancer 2002; 2: 
 657–672. 
 14 Yong V: Metalloproteinases: mediators of pa-
thology and regeneration in the CNS. Nat 
Rev Neurosci 2005; 6: 931–944. 
 15 Cauwe B, Opdenakker G: Intracellular sub-
strate cleavage: a novel dimension in the bio-
chemistry, biology and pathology of matrix 
metalloproteinases. Crit Rev Biochem Mol 
Biol 2010; 45: 351–423. 
16 Mannello F, Medda V: Nuclear localization 
of matrix metalloproteinases. Prog Histo-
chem Cytochem 2012; 47: 27–58.
 17 Mun-Bryce S, Rosenberg G: Matrix metal-
loproteinases in cerebrovascular disease. J 
Cereb Blood Flow Metab 1998; 18: 1163–1172. 
 18 Makowski G, Ramsby M: Binding of latent 
matrix metalloproteinase 9 to fibrin: activa-
tion via a plasmin-dependent pathway. In-
flammation 1998; 22: 287–305. 
 19 Pei D, Weiss SJ: Transmembrane-deletion 
mutants of the membrane-type matrix me-
talloproteinase-1 process progelatinase A 
and express intrinsic matrix-degrading ac-
tivity. J Biol Chem 1996; 271: 9135–9140. 
 20 Yana I, Weiss SJ: Regulation of membrane 
type-1 matrix metalloproteinase activation 
by proprotein convertases. Mol Biol Cell 
2000; 11: 2387–2401. 
 21 Overall CM, Kleifeld O: Towards third gen-
eration matrix metalloproteinase inhibitors 
for cancer therapy. Br J Cancer 2006; 94: 941–
946. 
 22 Murphy G, Stanton H, Cowell S, Butler G, 
Knäuper V, Atkinson S, Gavrilovic J: Mecha-
nisms for pro matrix metalloproteinase acti-
vation. APMIS 1999; 107: 38–44. 
 23 Fu X, Kassim SY, Parks WC, Heinecke JW: 
Hypochlorous acid generated by myeloper-
oxidase modifies adjacent tryptophan and 
glycine residues in the catalytic domain of 
matrix metalloproteinase-7 (matrilysin): an 
oxidative mechanism for restraining proteo-
lytic activity during inflammation. J Biol 
Chem 2003; 278: 28403–28409. 
 24 Yong V: The potential use of MMP inhibitors 
to treat CNS diseases. Expert Opin Investig 
Drugs 1999; 8: 255–268. 
 25 Peters DG, Kassam A, St Jean PL, Yonas H, 
Ferrell RE: Functional polymorphism in the 
matrix metalloproteinase-9 promoter as a 
potential risk factor for intracranial aneu-
rysm. Stroke 1999; 30: 2612–2616. 
 26 Wells JEA, Biernaskie J, Szymanska A, Lar-
sen PH, Yong VW, Corbett D: Matrix metal-
loproteinase (MMP)-12 expression has a 
negative impact on sensorimotor function 
following intracerebral haemorrhage in 
mice. Eur J Neurosci 2005; 21: 187–196. 
 27 Cunningham L, Wetzel M, Rosenberg G: 
Multiple roles for MMPs and TIMPs in cere-
bral ischemia. Glia 2005; 50: 329–339. 
 28 Wallace J, Alexander S, Estrada E, Hines C, 
Cunningham LA, Rosenberg GA: Tissue in-
hibitor of metalloproteinase-3 is associated 
with neuronal death in reperfusion injury. J 
Cereb Blood Flow Metab 2002;  22:  1303–
1310. 
 29 Aronowski J, Zhao X: Molecular pathophys-
iology of cerebral hemorrhage: secondary 
brain injury. Stroke 2011; 42: 1781–1786. 
 30 Zhao X, Sun G, Zhang J, Strong R, Dash PK, 
Kan YW, Grotta JC, Aronowski J: Transcrip-
tion factor Nrf2 protects the brain from 
damage produced by intracerebral hemor-
rhage. Stroke 2007; 38: 3280–3286. 
 31 Zhao X, Sun G, Zhang J, Strong R, Song W, 
Gonzales N, Grotta JC, Aronowski J: Hema-
toma resolution as a target for intracerebral 
hemorrhage treatment: role for peroxisome 
proliferator-activated receptor   in microg-
lia/macrophages. Ann Neurol 2007; 61: 352–
362. 
 32 Zhao X, Zhang Y, Strong R, Grotta JC, 
Aronowski J: 15d-Prostaglandin J2 activates 
peroxisome proliferator-activated receptor-
gamma, promotes expression of catalase, 
and reduces inflammation, behavioral dys-
function, and neuronal loss after intracere-
bral hemorrhage in rats. J Cereb Blood Flow 
Metab 2006; 26: 811–820. 
 33 Aronowski J, Hall C: New horizons for pri-
mary intracerebral hemorrhage treatment: 
experience from preclinical studies. Neurol 
Res 2005; 27: 268–279. 
 34 Nishino A, Suzuki M, Ohtani H, Motohashi 
O, Umezawa K, Nagura H, Yoshimoto T: 
Thrombin may contribute to the pathophys-
iology of central nervous system injury. J 
Neurotrauma 1993; 10: 167–179. 
 35 Feuerstein GZ, Wang X, Barone FC: The role 
of cytokines in the neuropathology of stroke 
and neurotrauma. Neuroimmunomodula-
tion 1998; 5: 143–159. 
 36 Tejima E, Zhao B-Q, Tsuji K, Rosell A, van 
Leyen K, Gonzalez RG, Montaner J, Wang X, 
Lo EH: Astrocytic induction of matrix me-
talloproteinase-9 and edema in brain hem-
orrhage. J Cereb Blood Flow Metab 2007; 27: 
 460–468. 
 37 Abbott NJ, Rönnbäck L, Hansson E: Astro-
cyte-endothelial interactions at the blood-
brain barrier. Nat Rev Neurosci 2006; 7: 41–53. 
 38 Power C, Henry S, Del Bigio M, Larsen PH, 
Corbett D, Imai Y, Yong VW, Peeling J:
Intracerebral hemorrhage induces macro-
phage activation and matrix metalloprotein-
ases. Ann Neurol 2003; 53: 731–742. 
 39 Mun-Bryce S, Wilkerson A, Pacheco B, 
Zhang T, Rai S, Wang Y, Okada Y: Depressed 
cortical excitability and elevated matrix me-
talloproteinases in remote brain regions fol-
lowing intracerebral hemorrhage. Brain Res 
2004; 1026: 227–234. 
 Florczak-Rzepka  /Grond-Ginsbach  /
Montaner  /Steiner  
Cerebrovasc Dis 2012;34:249–262262
 40 Dziedzic T: Clinical significance of acute 
phase reaction in stroke patients. Front Bio-
sci 2008; 13: 2922–2927. 
 41 Rosenberg GA, Estrada EY, Mobashery S: Ef-
fect of synthetic matrix metalloproteinase 
inhibitors on lipopolysaccharide-induced 
blood-brain barrier opening in rodents: dif-
ferences in response based on strains and 
solvents. Brain Res 2007; 1133: 186–192. 
 42 Castellanos M, Leira R, Serena J, Blanco M, 
Pedraza S, Castillo J, Dávalos A: Plasma
cellular-fibronectin concentration predicts 
hemorrhagic transformation after thrombo-
lytic therapy in acute ischemic stroke. Stroke 
2004; 35: 1671–1676. 
 43 Abilleira S, Montaner J, Molina CA, Monas-
terio J, Castillo J, Alvarez-Sabín J: Ma-
trix metalloproteinase-9 concentration after 
spontaneous intracerebral hemorrhage. J 
Neurosurg 2003; 99: 65–70. 
 44 Silva Y, Leira R, Tejada J, Lainez JM, Castillo 
J, Dávalos A; Stroke Project, Cerebrovascu-
lar Diseases Group of the Spanish Neurolog-
ical Society: Molecular signatures of vascu-
lar injury are associated with early growth of 
intracerebral hemorrhage. Stroke 2005; 36: 
 86–91. 
 45 Rosell A, Ortega-Aznar A, Alvarez-Sabín J, 
Fernández-Cadenas I, Ribó M, Molina CA, 
Lo EH, Montaner J: Increased brain expres-
sion of matrix metalloproteinase-9 after 
ischemic and hemorrhagic human stroke. 
Stroke 2006; 37: 1399–1406. 
 46 Wu H, Zhang Z, Hu X, Zhao R, Song Y, Ban 
X, Qi J, Wang J: Dynamic changes of inflam-
matory markers in brain after hemorrhagic 
stroke in humans: a postmortem study. 
Brain Res 2010; 1342: 111–117. 
 47 Wu C, Huang F, Wang K, Huang S, Yang RL, 
Li HZ, Lei HX, Lin JS, Wang JM, Yan XH: 
Expression of matrix metalloproteinase 
MMP-9 in the plasma and hematoma fluid of 
intracerebral hemorrhage patients (in Chi-
nese). Zhonghua Yi Xue Za Zhi 2008; 88: 174–
176.  
 48 Alvarez-Sabín J, Delgado P, Abilleira S, Mo-
lina CA, Arenillas J, Ribó M, Santamarina E, 
Quintana M, Monasterio J, Montaner J: Tem-
poral profile of matrix metalloproteinases 
and their inhibitors after spontaneous intra-
cerebral hemorrhage: relationship to clinical 
and radiological outcome. Stroke 2004; 35: 
 1316–1322. 
 49 Castellazzi M, Tamborino C, De Santis G, 
Garofano F, Lupato A, Ramponi V, Trentini 
A, Casetta I, Bellini T, Fainardi E: Timing of 
serum active MMP-9 and MMP-2 levels in 
acute and subacute phases after spontaneous 
intracerebral hemorrhage. Acta Neurochir 
Suppl 2010; 106: 137–140. 
 50 Yamani MH, Starling RC, Cook DJ, Tuzcu 
EM, Abdo A, Paul P, Powell K, Ratliff NB, Yu 
Y, McCarthy PM, Young JB: Donor sponta-
neous intracerebral hemorrhage is associat-
ed with systemic activation of matrix metal-
loproteinase-2 and matrix metalloprotein-
ase-9 and subsequent development of coro-
nary vasculopathy in the heart transplant 
recipient. Circulation 2003; 108: 1724–1728. 
 51 Lee J-M, Yin K, Hsin I, Chen S, Fryer JD, 
Holtzman DM, Hsu CY, Xu J: Matrix metal-
loproteinase-9 in cerebral-amyloid-angiopa-
thy-related hemorrhage. J Neurol Sci 2005; 
 229–230: 249–254. 
 52 Hernandez-Guillamon M, Martinez-Saez E, 
Delgado P, Domingues-Montanari S, Boada 
C, Penalba A, Boada M, Pagola J, Maisterra 
O, Rodriguez-Luna D, Molina CA, Rovira A, 
Alvarez-Sabin J, Ortega-Aznar A, Montaner 
J: MMP-2/MMP-9 plasma level and brain ex-
pression in cerebral amyloid angiopathy-as-
sociated hemorrhagic stroke. Brain Pathol 
2012; 22: 133–141. 
 53 Fujimura M, Watanabe M, Narisawa A, Shi-
mizu H, Tominaga T: Increased expression 
of serum matrix metalloproteinase-9 in pa-
tients with moyamoya disease. Surg Neurol 
2009; 72: 476–480, discussion 480. 
 54 Frösen J, Tulamo R, Paetau A, Laaksamo E, 
Korja M, Laakso A, Niemelä M, Hernesnie-
mi J: Saccular intracranial aneurysm: pa-
thology and mechanisms. Acta Neuropathol 
2012; 123: 773–786. 
 55 Hasan DM, Mahaney KB, Brown RD Jr, 
Meissner I, Piepgras DG, Huston J, Capuano 
AW, Torner JC; International Study of Un-
ruptured Intracranial Aneurysms Investiga-
tors: Aspirin as a promising agent for de-
creasing incidence of cerebral aneurysm 
rupture. Stroke 2011; 42: 3156–3162. 
 56 Chou SH-Y, Feske SK, Simmons SL, Konigs-
berg RG, Orzell SC, Marckmann A, Bourget 
G, Bauer DJ, De Jager PL, Du R, Arai K, Lo 
EH, Ning MM: Elevated peripheral neutro-
phils and matrix metalloproteinase 9 as bio-
markers of functional outcome following 
subarachnoid hemorrhage. Transl Stroke 
Res 2011; 2: 600–607. 
 57 Sarrafzadeh A, Copin J-C, Bengualid DJ, 
Turck N, Vajkoczy P, Bijlenga P, Schaller K, 
Gasche Y: Matrix metalloproteinase-9 con-
centration in the cerebral extracellular fluid 
of patients during the acute phase of aneuris-
mal subarachnoid hemorrhage. Neurol Res 
2012; 34: 455–461. 
 58 Wang J, Tsirka S: Neuroprotection by inhibi-
tion of matrix metalloproteinases in a mouse 
model of intracerebral haemorrhage. Brain 
2005; 128: 1622–1633. 
 59 Lee C, Xue Z, Zhu Y, Yang G, Young W: Ma-
trix metalloproteinase-9 inhibition attenu-
ates vascular endothelial growth factor-
induced intracerebral hemorrhage. Stroke 
2007; 38: 2563–2568. 
 60 Grossetete M, Rosenberg G: Matrix metal-
loproteinase inhibition facilitates cell death 
in intracerebral hemorrhage in mouse. J 
Cereb Blood Flow Metab 2007; 28: 752–763. 
 61 Lee S, Chu K, Jung K, Kim J, Kim EH, Kim 
SJ, Sinn DI, Ko SY, Kim M, Roh JK: Meman-
tine reduces hematoma expansion in experi-
mental intracerebral hemorrhage, resulting 
in functional improvement. J Cereb Blood 
Flow Metab 2005; 26: 536–544. 
 62 Sinn D-I, Kim S-J, Chu K, Jung KH, Lee ST, 
Song EC, Kim JM, Park DK, Kun Lee S, Kim 
M, Roh JK: Valproic acid-mediated neuro-
protection in intracerebral hemorrhage via 
histone deacetylase inhibition and tran-
scriptional activation. Neurobiol Dis 2007; 
 26: 464–472. 
 63 Wang X, Jung J, Asahi M, Chwang W, Russo 
L, Moskowitz MA, Dixon CE, Fini ME, Lo 
EH: Effects of matrix metalloproteinase-9 
gene knock-out on morphological and motor 
outcomes after traumatic brain injury. J 
Neurosci 2000; 20: 7037–7042. 
 64 Tang J, Liu J, Zhou C, Alexander JS, Nanda 
A, Granger DN, Zhang JH: MMP-9 deficien-
cy enhances collagenase-induced intracere-
bral hemorrhage and brain injury in mutant 
mice. J Cereb Blood Flow Metab 2004; 24: 
 1133–1145. 
 65 Zlokovic BV: Remodeling after stroke. Nat 
Med 2006; 12: 390–391. 
 
